
AZ reveals compelling PhIII data for ovarian cancer treatment
pharmafile | October 26, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |ย ย AZ, AstraZeneca, lynparzaย
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy for the treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.
The results showed that the drug achieved a statistically significant improvement of progression-free survival (PFS) in patients compared to placebo. Median PFS also substantially exceeded what the drug recorded in its Phase II trial studying patients with platinum-sensitive relapsed ovarian cancer. Safety findings remained consistent with earlier data.
The results follow the FDAโs decision to award Lynparza Fast Track Designation earlier this year.
โWe are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial,โ commented Sean Bohen, executive VP of Global Medicines Development and CMO at AstraZeneca. โWe will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine.โ
Matt Fellows
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZenecaโs benralizumab (Fasenra) as …

NICE approves AstraZenecaโs dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






